RRx-001是一种一流的MYC小分子抑制剂和CD47下调剂，是一种“红细胞吞噬免疫疗法”。
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic".
作者信息
Oronsky Bryan, Carter Corey A, Caroen Scott, Scribner Curtis, Oronsky Arnold, Reid Tony R
机构信息
Clinical and Scientific Department, EpicentRx, Inc, La Jolla, CA, USA.
Clinical and Scientific Department, InterWest Partners, Menlo Park, CA, USA.
出版信息
Oncoimmunology. 2020 Apr 3;9(1):1746172. doi: 10.1080/2162402X.2020.1746172.
Abstract
The main mechanism of action of RRx-001, a pharmaceutically unprecedented Phase 3 small molecule that is derived from the aerospace industry, is clarified. RRx-001 has demonstrated anticancer activity through antiangiogenic, immune, epigenetic, antioxidant, apoptotic and nitric oxide (NO) pathways, resulting in its pleiomorphic description as an antiangiogenic/vascular normalizer.
摘要
RRx-001是一种源自航空航天工业的、前所未有的3期小分子药物，其主要作用机制已得到阐明。RRx-001已通过抗血管生成、免疫、表观遗传、抗氧化、凋亡和一氧化氮（NO）途径展现出抗癌活性，因此被多方面描述为一种抗血管生成/血管正常化药物。
相似文献
1
RRx-001, a first-in-class small molecule inhibitor of MYC and a downregulator of CD47, is an "erythrophagoimmunotherapeutic".RRx-001是一种一流的MYC小分子抑制剂和CD47下调剂，是一种“红细胞吞噬免疫疗法”。
Oncoimmunology. 2020 Apr 3;9(1):1746172. doi: 10.1080/2162402X.2020.1746172.
2
RRx-001, a downregulator of the CD47- SIRPα checkpoint pathway, does not cause anemia or thrombocytopenia.RRx-001 是一种 CD47-SIRPα 检查点通路的下调调节剂，不会导致贫血或血小板减少症。
Expert Opin Drug Metab Toxicol. 2021 Apr;17(4):355-357. doi: 10.1080/17425255.2021.1876025. Epub 2021 Jan 22.
3
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.RRx-001 的发现：一种具有肿瘤靶向细胞毒性和健康组织细胞保护特性的 Myc 和 CD47 下调小分子化合物，目前处于临床开发阶段。
J Med Chem. 2021 Jun 10;64(11):7261-7271. doi: 10.1021/acs.jmedchem.1c00599. Epub 2021 May 27.
4
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.用表观遗传抗癌剂RRx-001靶向肿瘤缺氧：一种一氧化氮生成的超级激动剂。
Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. Epub 2016 Jul 4.
5
Superficial Venous-Associated Inflammation from Direct IV Administration of RRx-001 in Rats.大鼠直接静脉注射 RRx-001 引起的浅表静脉相关性炎症。
Int J Med Sci. 2022 Sep 21;19(11):1628-1630. doi: 10.7150/ijms.76615. eCollection 2022.
6
Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity.RRx-001的表观遗传效应：一种可能的抗癌活性统一机制。
Oncotarget. 2015 Dec 22;6(41):43172-81. doi: 10.18632/oncotarget.6526.
7
RRx-001 Acts as a Dual Small Molecule Checkpoint Inhibitor by Downregulating CD47 on Cancer Cells and SIRP-α on Monocytes/Macrophages.RRx-001通过下调癌细胞上的CD47和单核细胞/巨噬细胞上的信号调节蛋白α（SIRP-α），发挥双重小分子检查点抑制剂的作用。
Transl Oncol. 2019 Apr;12(4):626-632. doi: 10.1016/j.tranon.2018.12.001. Epub 2019 Feb 6.
8
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.免疫调节抗癌药物RRx-001通过病毒模拟的表观遗传诱导来引发干扰素反应。
Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.
9
Platelet inhibitory effects of the Phase 3 anticancer and normal tissue cytoprotective agent, RRx-001.RRx-001 是一种处于 III 期的抗癌和正常组织细胞保护剂，具有血小板抑制作用。
J Cell Mol Med. 2018 Oct;22(10):5076-5082. doi: 10.1111/jcmm.13791. Epub 2018 Jul 16.
10
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001.Nrf2活性作为泛表观遗传抗癌剂RRx-001的潜在生物标志物。
Oncotarget. 2015 Aug 28;6(25):21547-56. doi: 10.18632/oncotarget.4249.
引用本文的文献
1
Nitro-Group π System Drives the Interaction of RRx-001 with Electrons in Solution.硝基-π体系驱动RRx-001在溶液中与电子的相互作用。
Chemistry. 2025 Jun 3;31(31):e202500859. doi: 10.1002/chem.202500859. Epub 2025 May 9.
2
Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment.针对CD47-SIRPα信号通路的治疗策略在胃肠道癌症治疗中的应用
J Pharm Anal. 2025 Jan;15(1):101099. doi: 10.1016/j.jpha.2024.101099. Epub 2024 Sep 12.
3
Small molecule innate immune modulators in cancer therapy.小分子天然免疫调节剂在癌症治疗中的应用。
Front Immunol. 2024 Sep 10;15:1395655. doi: 10.3389/fimmu.2024.1395655. eCollection 2024.
4
Deciphering the role of CD47 in cancer immunotherapy.解析 CD47 在癌症免疫疗法中的作用。
J Adv Res. 2024 Sep;63:129-158. doi: 10.1016/j.jare.2023.10.009. Epub 2023 Oct 28.
5
RRx-001: a chimeric triple action NLRP3 inhibitor, Nrf2 inducer, and nitric oxide superagonist.RRx-001：一种嵌合型三重作用的NLRP3抑制剂、Nrf2诱导剂和一氧化氮超激动剂。
Front Oncol. 2023 May 29;13:1204143. doi: 10.3389/fonc.2023.1204143. eCollection 2023.
6
MYC inhibitors in multiple myeloma.多发性骨髓瘤中的MYC抑制剂
Cancer Drug Resist. 2021 Aug 13;4(4):842-865. doi: 10.20517/cdr.2021.55. eCollection 2021.
7
The Role of Macrophages in Cancer Development and Therapy.巨噬细胞在癌症发展与治疗中的作用
Cancers (Basel). 2021 Apr 18;13(8):1946. doi: 10.3390/cancers13081946.
本文引用的文献
1
RRx-001 protects normal tissues but not tumors via Nrf2 induction and Bcl-2 inhibition.RRx-001 通过诱导 Nrf2 和抑制 Bcl-2 来保护正常组织而不影响肿瘤。
J Cancer Res Clin Oncol. 2019 Aug;145(8):2045-2050. doi: 10.1007/s00432-019-02958-4. Epub 2019 Jun 27.
2
Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors.RRx-001在临床前肿瘤中药效学的磁共振成像
Oncotarget. 2017 Jun 12;8(60):102511-102520. doi: 10.18632/oncotarget.18455. eCollection 2017 Nov 24.
3
NO and HNO donors, nitrones, and nitroxides: Past, present, and future.NO 和 HNO 供体、硝酮和氮氧自由基：过去、现在和未来。
Med Res Rev. 2018 Jul;38(4):1159-1187. doi: 10.1002/med.21461. Epub 2017 Nov 2.
4
The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.免疫调节抗癌药物RRx-001通过病毒模拟的表观遗传诱导来引发干扰素反应。
Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. eCollection 2017.
5
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.RRx-001：一种正在进行II期临床试验的全身无毒的M2型巨噬细胞刺激和致敏剂。
Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600.
6
Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation.用表观遗传抗癌剂RRx-001靶向肿瘤缺氧：一种一氧化氮生成的超级激动剂。
Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. Epub 2016 Jul 4.
7
RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors.RRx-001是一种基于表观遗传学的放射和化学增敏剂，对SCCVII和U87肿瘤具有血管正常化作用。
Clin Epigenetics. 2016 May 11;8:53. doi: 10.1186/s13148-016-0220-7. eCollection 2016.
8
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001.对癌症说“不”：一氧化氮及表观遗传一氧化氮供体RRx-001的复杂多面作用
Redox Biol. 2015 Dec;6:1-8. doi: 10.1016/j.redox.2015.07.002. Epub 2015 Jul 2.
9
Preclinical evaluation of the metabolism and disposition of RRx-001, a novel investigative anticancer agent.RRx-001 新型抗癌药物的临床前代谢和处置研究。
Drug Metab Dispos. 2012 Sep;40(9):1810-6. doi: 10.1124/dmd.112.046755. Epub 2012 Jun 14.
Zotero 插件